

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD4

RRID:AB_2737961

Type: Antibody

Proper Citation

BD Biosciences Cat# 563028, RRID:AB_2737961

Antibody Information

URL: http://antibodyregistry.org/AB_2737961

Proper Citation: BD Biosciences Cat# 563028, RRID:AB_2737961

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: SK3 (also known as Leu3a)

Antibody ID: AB_2737961

Vendor: BD Biosciences

Catalog Number: 563028

Record Creation Time: 20250819T222929+0000

Record Last Update: 20250820T022151+0000

Ratings and Alerts

No rating or validation information has been found for CD4.

No alerts have been found for CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. Cell reports. Medicine, 6(6), 102148.

Monberg TJ, et al. (2025) Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. Cell reports. Medicine, 6(3), 102016.

Bekkering S, et al. (2024) Increased innate immune responses in adolescents with obesity and its relation to subclinical cardiovascular measures: An exploratory study. iScience, 27(5), 109762.

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell, 187(2), 390.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer cell, 40(9), 1010.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer cell, 39(2), 257.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347.

Du H, et al. (2019) Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer cell, 35(2), 221.